Fishing for oncology new product gems

One of my favourite exercises at conferences is exploring new or emerging targets in the the poster halls, either in the context of preclinical or early phase 1 data.

Undoubtedly it often ends up as a bit of a fishing expedition – you have all the anticipation and excitement upfront and just as in real life, sometimes you go home empty when nothing bites as happened to a couple of guys I was watching fishing in the bayou last weekend!

Much to their frustration, the mullet gleefully jumped around them without going near.

Assessing early stage oncology pipeline development is a bit like this too.  After following this particular niche for a while, it was time to take stock with a new clinical readout available.

Did the data live up to expectations or not?

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by